Visalytics
Visalytics
approved EB-2 (NIW)

Validation Specialist

Materials Science And Engineering · Indonesia · 2025-10-28

Processing Time
634 days
Decision Date
2025-10-28
Location
Kentucky
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to streamline pre-formulation and formulation processes to enhance oral drug delivery and pharmaceutical manufacturing efficiency. This work utilizes advanced materials science techniques for pharmaceutical characterization to improve patient outcomes and create sustainable production practices. The endeavor aims to advance critical life-sciences technology sectors within the U.S. healthcare system.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses pharmaceutical manufacturing efficiency and oral drug delivery, which are critical to the U.S. healthcare system.

2 Well-positioned to Advance the Endeavor Met

The petitioner's M.S. degree, patent, and publication record in prestigious journals like Nature demonstrate the ability to lead impactful research.

3 Balance of Factors to Waive Job Offer Met

The widespread reliance on the petitioner's findings, evidenced by 433 citations, indicates that the U.S. benefits more from the petitioner's work than from requiring a labor certification.

Why This Petition Was Approved

The petition was approved based on the petitioner's record of 3 peer-reviewed journal articles, one patent, and 433 citations, demonstrating significant influence in the field. The case was supported by four expert recommendation letters and evidence of research funding from major agencies like the NSF, ARO, and DOE. All three Dhanasar prongs were satisfied without the issuance of an RFE.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Patents
Reference Letters Dependent
Grants
Government Alignment

Similar Cases

Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) rfe approved
North Carolina 111 days 2025-02-08
The petitioner proposes to improve existing therapies by applying advanced pharmaceutical principles to commercialize biopharmaceuticals and pharmaceuticals. The work focuses on developing innovative drug solubility enhancement methods and non-invasive oral drug delivery systems to treat serious diseases like cancer, AIDS, and kidney failure.
View Case

Chemist

Pharmaceuticals · India

WeGreened EB-2 (NIW) approved
New Jersey 47 days 2025-07-30
The petitioner proposes to apply pharmaceutical science methodologies to streamline drug development and ensure regulatory compliance. Her work focuses on formulation development, analytical validation, and regulatory strategy improvement to reduce the time and cost of bringing drug compounds from the lab to the market.
View Case

Others

Pharmaceuticals · South Korea

WeGreened EB-2 (NIW) approved
54 days 2025-03-24
The petitioner proposes to continue her research in pharmaceutical science by integrating advanced technologies and computational approaches to develop novel drug candidates. Her work focuses on improving drug delivery systems to create more effective, affordable, and stable medications for chronic diseases including cancer, diabetes, hypertension, and neurodegenerative diseases.
View Case

Postdoctoral Researcher

Chemicals · India

WeGreened EB-2 (NIW) approved
Massachusetts 156 days 2022-10-04
The petitioner proposes to continue research on developing state-of-the-art drug delivery approaches that cross biological interfaces. This work focuses on enabling the facile treatment of a wide range of disorders, including neurological disorders, metastatic cancer, and COVID-19, through protein-based therapies.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from Indonesia

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-10-28.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 634 days
Criteria Met 3 / 3
Evidence Types 6

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,895
Success Rate 54.2%
Sustained 2,112
Dismissed 1,687

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Indonesia All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist